

Updates on the SIERRA Trial: An Investigation of Apamistamab-I-131

Sergio A. Giralt, MD

Chief Attending, BMT Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College
New York, New York

Welcome to *Managing AML*. I am Dr. Sergio Giralt and I would like to briefly discuss the updates on the [SIERRA trial](#) on AML. The SIERRA trial is a randomized phase 3 trial of an investigational radio-immune conjugate called lomab (apamistamab-I-131). Lomab is a CD45 monoclonal antibody that has been conjugated with a radioactive iodine. This study is now being performed across the country in more than 15 centers and it is for patients with acute myelogenous leukemia who have active disease after two lines of initial induction therapy. Patients are randomized to either receive lomab and then go on to a reduced intensity conditioning regimen with fludarabine TBI or the control group to receive dealer's choice induction therapy and then if they achieve a remission to proceed to an allogeneic transplant as deemed appropriate by the investigator. So the trial continues to accrue. We are encouraged that the results on lomab showed that patient's randomized to lomab were all able to get the treatment to they have done was associated with the expected toxicities that were seen in the phase 2 and engraftment after lomab was as expected. We will be hearing future updates of the SIERRA trial, and hopefully it will be fully complete and ready for presentation at the end of 2020 or beginning of 2021.

Thank you for viewing this activity.